Kontos

Anokion (formerly known as Kontos Therapeutics) is a clinical-stage biotechnology company focused on treating autoimmune diseases by restoring normal immune tolerance. The company's proprietary platform leverages the body's natural processes for clearing aging cells to deliver specific antigens to the liver, where they induce immune tolerance rather than an inflammatory response. Their lead program, KAN-101, is currently in Phase 2 clinical trials for the treatment of celiac disease. By engineering antigens to target natural tolerance pathways, Anokion aims to provide disease-modifying therapies that eliminate the need for broad immunosuppression.